The "Shape Shifters": How Nitazenes Are Quietly Redefining the American Overdose Crisis

This article was co-published with Signal Ohio and STAT.

The death of 29-year-old Ashley Delgado was not an anomaly; it was a symptom of a lethal, evolving paradigm in the American illicit drug trade. In high school, Delgado was a high-achieving student with dreams of becoming a doctor—a path she hoped would one day allow her to provide for her father, James Taylor. “She wanted to heal people,” Taylor recalls, noting her aptitude for science and Latin. But a leg injury in her mid-20s led to an OxyContin prescription, triggering a decade-long struggle with addiction that progressed from prescription pills to heroin, methamphetamine, and eventually, the increasingly contaminated street supply of fentanyl.

On a summer morning in 2023, Delgado was found dead on a desolate street outside Cleveland. A single sandal was missing. Tucked into her clothing was a scrap of paper containing a mysterious tan powder. Toxicology reports later confirmed the presence of protonitazene and metonitazene—synthetic opioids from a class known as nitazenes.

While the public remains focused on the well-documented horrors of the fentanyl epidemic, a more potent, more obscure class of synthetic opioids is infiltrating the U.S. border. Nitazenes, substances developed in the 1950s but abandoned for medical use due to extreme toxicity, are now being trafficked into the American heartland, often without the knowledge of the very people consuming them.

The Chronology of a Deadly Evolution

The emergence of nitazenes is a masterclass in the "arms race" between global drug manufacturers and international law enforcement.

• 1950s: Nitazenes are synthesized by pharmaceutical researchers but are discarded as too dangerous for human medical application.
• 2014: The U.S. Drug Enforcement Administration (DEA) begins monitoring nitazene-related seizures.
• 2019: Following a global crackdown on fentanyl-related substances, China bans all fentanyl analogues. Simultaneously, reports of nitazenes in the U.S. begin a sharp, sustained increase.
• 2021–2024: Nitazenes permeate the U.S. supply. Data from the Centers for Disease Control and Prevention (CDC) records over 1,100 confirmed fatalities, though experts suspect the actual death toll is nearly double that figure.
• 2025: China places the majority of nitazenes under national control. Manufacturers pivot to "orphines"—chemically similar substances designed to skirt regulations.

For families like James Taylor’s, the timeline is marked not by policy shifts, but by profound, irreversible loss. “I have lost my father, my grandmother—that hurts,” Taylor said. “But when you lose your child, that’s the worst thing on the planet, because they’re not supposed to go before you.”

Data: The Invisible Surge

The true scale of the nitazene crisis is masked by a significant testing gap. According to Alex Krotulski, director of the Centre for Forensic Science Research and Education, deaths are chronically underreported because standard forensic toxicology panels often do not test for these compounds.

"There are only limited forensic toxicology labs that test for nitazenes," Krotulski noted. "So if a nitazene was present and the lab didn’t test for it, the number wouldn’t appear in official reports."

Despite this, the data that does exist is harrowing. Figures from the United Nations Office on Drugs and Crime (UNODC) reveal that the United States has reported 26 different varieties of nitazenes since 2019, ranking second globally only to Canada. In the U.S., the DEA’s National Forensic Laboratory Information System (NFLIS) shows confirmed seizures rising from 43 in 2019 to nearly 2,000 by 2024. By March of this year, total reports topped 8,000.

Ohio has emerged as the epicenter of this crisis. NFLIS data indicates that more than a third of all positive nitazene lab reports nationally are linked to the state. Within Ohio, counties like Scioto, Butler, and Cuyahoga—already reeling from decades of opioid overprescribing—bear the heaviest burden.

The "Dealer’s Choice": A Poly-Drug Nightmare

Bellingcat’s investigation into medical examiner reports in Cuyahoga County reveals a sobering reality: nitazenes are rarely consumed alone. Of 45 nitazene-related deaths between 2023 and 2024, the victims were found to have ingested a "cocktail" of substances, including fentanyl, cocaine, methamphetamine, and benzodiazepines.

Frank Tarentino, Associate Chief of Operations for the DEA’s Northeast Region, explains that this is a strategic move by traffickers. "We used to see organizations that were predominantly selling and transporting cocaine or just heroin or just methamphetamine," Tarentino said. "Now, we’re seeing organizations move everything. We see these poly-drug organizations, and we see these poly-drug mixtures."

The economic incentive is simple: nitazenes are incredibly potent—some up to 40 times stronger than fentanyl and 500 times stronger than heroin. Dealers can purchase a kilogram of raw nitazene for between $4,000 and $40,000, then dilute it into millions of doses. By mixing these potent chemicals into cheaper, more common street drugs, dealers create a "brand" of heightened potency that keeps users addicted while significantly increasing the likelihood of fatal respiratory failure.

Official Responses and Border Vulnerabilities

The U.S. government has responded with a multi-pronged approach, including indictments of Chinese chemical manufacturing firms, the imposition of tariffs, and undercover operations to dismantle digital supply chains. Freedom of Information Act requests to U.S. Customs and Border Protection (CBP) show that while seizures are occurring, the supply chain is highly fragmented.

Most shipments consist of small parcels—ranging from less than a gram to 700 grams—shipped via mail from China, Hong Kong, or the United Kingdom. However, occasional larger busts, such as the seizure of 100,000 pills containing isotonitazene from a vehicle crossing the Canadian border, demonstrate that organized traffickers are also involved in high-volume smuggling.

Yet, as soon as one substance is scheduled, the "Hydra" of the illicit market evolves. The emergence of "orphines"—synthetic opioids with slight molecular variations designed to bypass international bans—illustrates the futility of a purely reactionary approach. Experts warn that as long as there is demand, manufacturers will continue to exploit the "shape-shifting" nature of chemical regulations.

Implications for Public Health

The rise of nitazenes demands a shift in public health strategy. Organizations like Harm Reduction Ohio are pushing for expanded access to drug-checking services and wider distribution of Naloxone.

"People are going to use drugs," says AmandaLynn Reese, chief program officer at Harm Reduction Ohio. "We don’t know the supply, but those are ways you can engage in your drug use to increase safety and reduce harm."

The human cost, however, remains the most stark implication. The victims in the Cuyahoga County records included university graduates, veterans, ironworkers, and addiction counselors—proof that the crisis does not discriminate by socio-economic status.

As the U.S. faces the prospect of yet another wave of synthetic opioids, the case of Ashley Delgado serves as a haunting reminder of the stakes. For the parents, the partners, and the communities left behind, the "war on drugs" is not a political debate or a statistical analysis—it is a daily, desperate struggle against an invisible and ever-adapting predator.

With the illicit market showing no signs of slowing down, the question remains whether the current regulatory framework can ever keep pace with the manufacturers who view human lives as acceptable collateral in a global game of chemical profit.

Reporting for this story was supported by the Fund for Investigative Journalism.